SEC inquiry
This article was originally published in The Tan Sheet
Executive Summary
Schering receives "Wells Notice" March 11 notifying firm of SEC staff decision to recommend the commission bring a civil action against firm and CEO Richard Kogan regarding Oct. 3 earnings warning, which was preceded by closed-door investor meetings (1"The Tan Sheet" Nov. 18, 2003, p. 13). Schering can now file legal brief...
You may also be interested in...
Schering’s Rocky Succession: Former Mining Exec To Head CEO Search
Schering-Plough interim Chairman Richard Osborne is likely to be wary of mergers as a turnaround strategy for the company
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.